Complexin 2 or CPLX2 or CPX-2 or Synaphin 1 is a protein-encoding gene.
Function[edit | edit source]
ME/CFS[edit | edit source]
The ME/CFS Gene Study is still collecting data, but the pilot study publication by Perez et al. (2019) found that CPLX2 was one of the ten relatively common genes or gene variants that were both significantly more common in people with ME/CFS, and likely to be harmful.
Notable studies[edit | edit source]
- 2019, Genetic Predisposition for Immune System, Hormone, and Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study(Full text)
See also[edit | edit source]
Learn more[edit | edit source]
- CPLX2 Gene - Gene card
References[edit | edit source]
- "Complexin 2 - Gene card". Gene cards. Retrieved May 25, 2022.
- Nathanson, Lubov; Craddock, Travis J.A.; Klimas, Nancy G.; Gemayel, Kristina; Del Alamo, Ana; Hilton, Kelly; Jaundoo, Rajeev; Perez, Melanie (2019). "Genetic Predisposition for Immune System, Hormone, and Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study". Frontiers in Pediatrics. 7: 206. doi:10.3389/fped.2019.00206. ISSN 2296-2360.
myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.